2021
Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer
Laird J, Leventhal J, Kanowitz J, Damast S. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer. Practical Radiation Oncology 2021, 11: 448-452. PMID: 34157449, DOI: 10.1016/j.prro.2021.06.001.Peer-Reviewed Original Research
2018
Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies
Ma J, Laird J, Chau K, Chelius M, Lok B, Yahalom J. Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies. Cancer Medicine 2018, 8: 58-66. PMID: 30597769, PMCID: PMC6346231, DOI: 10.1002/cam4.1844.Peer-Reviewed Original ResearchConceptsLangerhans cell histiocytosisAdult LCH patientsAdditional malignanciesLCH patientsLCH diagnosisCell histiocytosisSolid malignanciesHigh prevalenceSingle institution experienceCause of malignancyYears of ageOncologic historyConsecutive patientsMedian ageHistiocyte proliferationHematologic malignanciesRare disorderLCH treatmentRare diseasePatientsMalignancySolid tumorsTumorigenic agentsHistiocytosisCohort
2017
Unravelling the biology of SCLC: implications for therapy
Sabari J, Lok B, Laird J, Poirier J, Rudin C. Unravelling the biology of SCLC: implications for therapy. Nature Reviews Clinical Oncology 2017, 14: 549-561. PMID: 28534531, PMCID: PMC5843484, DOI: 10.1038/nrclinonc.2017.71.Peer-Reviewed Original ResearchConceptsBiology of SCLCHigh-grade neuroendocrine tumorsPARP inhibitor veliparibImmune checkpoint blockadeEncouraging clinical activityPoor overall survivalHigh mutational burdenImmune checkpoint proteinsZeste homologue 2Antibody-drug conjugatesOverall survivalRovalpituzumab tesirineLung cancerNeuroendocrine tumorsClinical trialsClinical activityMutational burdenNew therapiesTherapeutic targetingProtein 3SCLCHomologue 2PatientsPromising activityTherapy